von Bueren, André O.

[["dc.bibliographiccitation.artnumber","e0121592"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Pietschmann, Sophie"],["dc.contributor.author","von Bueren, Andre Oscar"],["dc.contributor.author","Kerber, Michael Josef"],["dc.contributor.author","Baumert, Brigitta G."],["dc.contributor.author","Kortmann, Rolf Dieter"],["dc.contributor.author","Mueller, Klaus"],["dc.date.accessioned","2018-11-07T09:58:35Z"],["dc.date.available","2018-11-07T09:58:35Z"],["dc.date.issued","2015"],["dc.description.abstract","Purpose To determine the characteristics, treatments and outcomes of patients with glioblastoma multiforme (GBM) or gliosarcoma (GS) and metastases outside of the central nervous system (CNS). Methods PubMed and Web of Science searches for peer-reviewed articles pertaining to GBM/GS patients with metastatic dissemination were conducted using the keywords gliosarcoma, glioblastoma, GBM, metastasis, metastases and metastatic. Additionally, we performed hand search following the references from the selected papers. Cases with metastases to the CNS were excluded and evaluated in a separate study. Results 109 articles published between 1928 and 2013 were eligible. They reported on 150 patients. We observed a remarkable increase in the number of cases per decade over time. Median overall survival from diagnosis of metastasis (OSM+) was 6.0 +/- 0.8 months and median overall survival from initial diagnosis (OSID) 13 +/- 2.4 months. On univariate analyses, gender, age, the histological subtype, the time interval between initial diagnosis and diagnosis of metastasis and pulmonary involvement did not influence OSM+. We did not observe any substantial treatment progress. A comparison of the present cohort with 84 GBM/GS patients with exclusive CNS dissemination suggests that metastases outside the CNS are related to a slightly more favorable outcome. Conclusions The occurrence of extra-CNS metastasis from GBM/GS is associated with a dismal prognosis, however it seems to compare slightly favorable to CNS dissemination. Crucial treatment progress has not been achieved over recent decades. A central registry should be considered to consecutively gain more information about the ideal therapeutic approach."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2015"],["dc.identifier.doi","10.1371/journal.pone.0121592"],["dc.identifier.isi","000352590300027"],["dc.identifier.pmid","25860797"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11782"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37392"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","An Individual Patient Data Meta-Analysis on Characteristics, Treatments and Outcomes of Glioblastoma/Gliosarcoma Patients with Metastases Outside of the Central Nervous System"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","161"],["dc.bibliographiccitation.journal","Radiation Oncology"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Scholtyssek, Felix"],["dc.contributor.author","Zwiener, Isabella"],["dc.contributor.author","Schlamann, Annika"],["dc.contributor.author","Seidel, Clemens"],["dc.contributor.author","Meixensberger, Juergen"],["dc.contributor.author","Bauer, Manfred"],["dc.contributor.author","Hoffmann, Karl-Titus"],["dc.contributor.author","Combs, Stephanie E."],["dc.contributor.author","von Bueren, Andre Oscar"],["dc.contributor.author","Kortmann, Rolf-Dieter"],["dc.contributor.author","Mueller, Klaus"],["dc.date.accessioned","2018-11-07T09:22:30Z"],["dc.date.available","2018-11-07T09:22:30Z"],["dc.date.issued","2013"],["dc.description.abstract","Purposes: First, to evaluate outcome, the benefit of concurrent chemotherapy and prognostic factors in a cohort of sixty-four high-grade glioma patients who underwent a second course of radiation therapy at progression. Second, to validate a new prognostic score for overall survival after reirradiation of progressive gliomas with an independent patient cohort. Patients and methods: All patients underwent fractionated reirradiation with a median physical dose of 36 Gy. Median planned target volume was 110.4 ml. Thirty-six patients received concurrent chemotherapy consisting in 24/36 cases (67%) of carboplatin and etoposide and in 12/36 cases (33%) of temozolomide. We used the Kaplan Meier method, log rank test and proportional hazards regression analysis for statistical assessment. Results: Median overall survival from the start of reirradiation was 7.7 +/- 0.7 months. Overall survival rates at 6 and 12 months were 60 +/- 6% and 24 +/- 6%, respectively. Despite relatively large target volumes we did not observe any major acute toxicity. Concurrent chemotherapy did not appear to improve outcome. In contrast, female gender, young age, WHO grade III histology, favorable Karnofsky performance score and complete resection of the tumor prior to reirradiation were identified as positive prognostic factors for overall survival. We finally validated a recent suggestion for a prognostic score with our independent but small patient cohort. Our preliminary findings suggest that its ability to discriminate between different prognostic groups is limited. Conclusions: Outcome of our patients was comparable to previous studies. Even in case of large target volumes reirradiation seems to be feasible without observing major toxicity. The benefit of concurrent chemotherapy is still elusive. A reassessment of the prognostic score, tested in this study, using a larger patient cohort is needed."],["dc.identifier.doi","10.1186/1748-717X-8-161"],["dc.identifier.isi","000321565200001"],["dc.identifier.pmid","23822643"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/9136"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29353"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1748-717X"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Reirradiation in progressive high-grade gliomas: outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patient cohort"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e101211"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Schlamann, Annika"],["dc.contributor.author","von Bueren, Andre Oscar"],["dc.contributor.author","Hagel, Christian"],["dc.contributor.author","Zwiener, Isabella"],["dc.contributor.author","Seidel, Clemens"],["dc.contributor.author","Kortmann, Rolf-Dieter"],["dc.contributor.author","Mueller, Klaus"],["dc.date.accessioned","2018-11-07T09:37:49Z"],["dc.date.available","2018-11-07T09:37:49Z"],["dc.date.issued","2014"],["dc.description.abstract","Background and Purpose: In 2007, the WHO classification of brain tumors was extended by three new entities of glioneuronal tumors: papillary glioneuronal tumor (PGNT), rosette-forming glioneuronal tumor of the fourth ventricle (RGNT) and glioneuronal tumor with neuropil-like islands (GNTNI). Focusing on clinical characteristics and outcome, the authors performed a comprehensive individual patient data (IPD) meta-analysis of the cases reported in literature until December 2012. Methods: PubMed, Embase and Web of Science were searched for peer-reviewed articles reporting on PGNT, RGNT, and GNTNI using predefined keywords. Results: 95 publications reported on 182 patients (PGNT, 71; GNTNI, 26; RGNT, 85). Median age at diagnosis was 23 years (range 4-75) for PGNT, 27 years (range 6-79) for RGNT, and 40 years (range 2-65) for GNTNI. Ninety-seven percent of PGNT and 69% of GNTNI were located in the supratentorial region, 23% of GNTNI were in the spinal cord, and 80% of RGNT were localized in the posterior fossa. Complete resection was reported in 52 PGNT (73%), 36 RGNT (42%), and 7 GNTNI (27%) patients. Eight PGNT, 3 RGNT, and 12 GNTNI patients were treated with chemo- and/or radiotherapy as the primary postoperative treatment. Follow-up data were available for 132 cases. After a median follow-up time of 1.5 years (range 0.2-25) across all patients, 1.5-year progression-free survival rates were 52 +/- 12% for GNTNI, 86 +/- 5% for PGNT, and 100% for RGNT. The 1.5-year overall-survival were 95 +/- 5%, 98 +/- 2%, and 100%, respectively. Conclusions: The clinical understanding of the three new entities of glioneuronal tumors, PGNT, RGNT and GNTNI, is currently emerging. The present meta-analysis will hopefully contribute to a delineation of their diagnostic, therapeutic, and prognostic profiles. However, the available data do not provide a solid basis to define the optimum treatment approach. Hence, a central register should be established."],["dc.description.sponsorship","German Research Foundation (DFG); Leipzig University"],["dc.identifier.doi","10.1371/journal.pone.0101211"],["dc.identifier.isi","000341253400049"],["dc.identifier.pmid","24991807"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10485"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32927"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","An Individual Patient Data Meta-Analysis on Characteristics and Outcome of Patients with Papillary Glioneuronal Tumor, Rosette Glioneuronal Tumor with Neuropil-Like Islands and Rosette Forming Glioneuronal Tumor of the Fourth Ventricle"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0148312"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Beyer, Stefanie"],["dc.contributor.author","von Bueren, Andre Oscar"],["dc.contributor.author","Klautke, Gunther"],["dc.contributor.author","Guckenberger, Matthias"],["dc.contributor.author","Kortmann, Rolf-Dieter"],["dc.contributor.author","Pietschmann, Sophie"],["dc.contributor.author","Mueller, Klaus"],["dc.date.accessioned","2018-11-07T10:18:17Z"],["dc.date.available","2018-11-07T10:18:17Z"],["dc.date.issued","2016"],["dc.description.abstract","Our aim was to determine the characteristics, treatments and outcomes of patients with primary spinal glioblastomas (GB) or gliosarcomas (GS) reported in literature until March 2015. PubMed and Web of Science were searched for peer-reviewed articles pertaining to cases of glioblastomas / gliosarcomas with primary spinal origin, using predefined search terms. Furthermore we performed hand searches tracking the references from the selected papers. Eighty-two articles published between 1938 and March 2015 were eligible. They reported on 157 patients. Median age at diagnosis was 22 years. The proportion of patients who received adjuvant chemo-or radiotherapy clearly increased from the time before 1980 until present. Median overall survival from diagnosis was 8.0 +/- 0.9 months. On univariate analysis age influenced overall survival, whereas tumor location, gender and the extent of initial resection did not. Outcomes did not differ between children (< 18 years) and adults. However, the patients who were treated after 1980 achieved longer survival times than the patients treated before. On multivariable analysis only age (< 60 years) and the time period of treatment (>= 1980) were confirmed as positive independent prognostic factors. In conclusion, primary spinal GB / GS mainly affect younger patients and are associated with a dismal prognosis. However, most likely due to the increasing use of adjuvant treatment, modest therapeutic progress has been achieved over recent decades. The characteristics and treatments of primary spinal glioblastomas should be entered into a central registry in order to gain more information about the ideal treatment approach in the future."],["dc.description.sponsorship","German Research Foundation (DFG); University of Leipzig"],["dc.identifier.doi","10.1371/journal.pone.0148312"],["dc.identifier.isi","000370038400029"],["dc.identifier.pmid","26859136"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13132"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41406"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","A Systematic Review on the Characteristics, Treatments and Outcomes of the Patients with Primary Spinal Glioblastomas or Gliosarcomas Reported in Literature until March 2015"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]